Lundbeck Begins Next Stage Migraine Treatment Trial

H. Lundbeck, a Denmark-based pharmaceutical firm, is running a stage two study, labelled PROCEED, to further test a potential migraine prevention treatment.

This follows a successful study, HOPE Phase IIa, which showed that the migraine therapy, administered directly into the vein, was effective in preventing migraines.  

The study has the objective of finding the most efficient dose of the migraine medication by testing four different dosages given as a shot once monthly for three months and the study will be conducted in Europe, Japan, and the US.   

Johan Luthman, Lundbeck research and development lead, commented, “Initiation of this Phase IIb trial of Lu AG09222 further progresses our neurology pipeline and emphasises Lundbeck’s commitment to people living with migraine and headache-related disorders.”  

Luthman went on to add, “The diverse nature of the disease highlights the need for exploring novel therapeutic approaches that can address unmet needs.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.